Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 5/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29915641 | 1.00 | MCHR1 (0.49) | MCHR1XDHIRAK4DHFRDCPS | |
| SCHEMBL16650978 | 0.84 | RIPK1 (0.41) | MCHR1XDH | |
| SCHEMBL21633961 | 0.83 | MCHR1 (0.43) | MCHR1XDHIRAK4GRM4BRD4 | |
| SCHEMBL30126151 | 0.83 | MCHR1 (0.49) | MCHR1XDHIRAK4DHFRDCPS | |
| SCHEMBL21652799 | 0.83 | CYP1A2 (0.43) | MCHR1IRAK4BRD4 | |
| SCHEMBL30126942 | 0.83 | MCHR1 (0.49) | MCHR1XDHIRAK4DHFRDCPS | |
| SCHEMBL30126836 | 0.83 | MCHR1 (0.49) | MCHR1XDHIRAK4DHFRDCPS | |
| SCHEMBL23436644 | 0.80 | MCHR1 (0.41) | MCHR1XDHIRAK4GRM4BRD4 | |
| SCHEMBL21634036 | 0.78 | CYP19A1 (0.42) | MCHR1XDHIRAK4BRD4 | |
| SCHEMBL30127315 | 0.76 | XDH (0.55) | MCHR1XDHDHFRDCPSFFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| CN-115716827-A | Iminosulfones compound as bromodomain protein inhibitor, pharmaceutical composition and medical application thereof | 正大天晴药业集团股份有限公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-112424200-B | Iminosulfones compound as bromodomain protein inhibitor, pharmaceutical composition and medical application thereof | 正大天晴药业集团股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| EP-3828183-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-06-02 | — | — | EP | disclosed |
| EP-3828183-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-06-02 | — | — | EP | disclosed |
| CN-112424200-A | Iminosulfones compound as bromodomain protein inhibitor, pharmaceutical composition and medical application thereof | 正大天晴药业集团股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2020020288-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | BRD1, BRD4, BRD2 | MCHR1 4755/4885XDH 945/4885IRAK4 1981/4885 |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | BRD4, BRD1, BRD3 | MCHR1 4707/4885XDH 3179/4885IRAK4 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.